Trial · NCT00589784

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2016-01-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma. Trials, record NCT00589784. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00589784

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
NCT number: NCT00589784
Status: Completed
Phases: Phase 2
Enrollment: 50 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions: Sunitinib
First posted: 2008-01-10
Last updated: 2016-01-25
Results first posted: 2016-01-25

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Objective Response	1.5 years	Determine the overall objective response

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Objective Response	1.5 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Overall Objective Response	Aggressive Memingioma	Complete Response	1	participants
Overall Objective Response	Exploratory Cohort	Complete Response	0	participants
Overall Objective Response	Aggressive Memingioma	Partial Response	1	participants
Overall Objective Response	Exploratory Cohort	Partial Response	0	participants
Overall Objective Response	Aggressive Memingioma	Progression of Disease	8	participants
Overall Objective Response	Exploratory Cohort	Progression of Disease	4	participants
Overall Objective Response	Aggressive Memingioma	Stable Disease	25	participants
Overall Objective Response	Exploratory Cohort	Stable Disease	0	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Aggressive Memingioma	36
Overall Study	STARTED	Exploratory Cohort	14
Overall Study	COMPLETED	Aggressive Memingioma	35
Overall Study	COMPLETED	Exploratory Cohort	4
Overall Study	NOT COMPLETED	Aggressive Memingioma	1
Overall Study	NOT COMPLETED	Exploratory Cohort	10

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Leukopenia	Blood and lymphatic system disorders	All Patients	31	50	31
other	Fatigue	General disorders	All Patients	29	50	29
other	Thrombocytopenia	Respiratory, thoracic and mediastinal disorders	All Patients	23	50	23
other	Diarrhea	Gastrointestinal disorders	All Patients	22	50	22
other	Hypoalbuminemia	Metabolism and nutrition disorders	All Patients	19	50	19
other	AST	Blood and lymphatic system disorders	All Patients	19	50	19
other	ALT	Blood and lymphatic system disorders	All Patients	17	50	17
other	Nausea	Gastrointestinal disorders	All Patients	17	50	17
other	Hyperglycemia	Metabolism and nutrition disorders	All Patients	16	50	16
other	Rash, Hand-Foot Reaction	Skin and subcutaneous tissue disorders	All Patients	16	50	16

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Patients
Total, other adverse events	All Patients	50	50
Total, serious adverse events	All Patients	27	50

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00589784

GET https://conductscience.org/api/trials/v1/NCT00589784/events?page=2

API reference For AI assistants